Clinical, etiological, and therapeutic profile of early-onset absence seizures: A case series analysis

Patrizia Bergonzini1, Elisa Caramaschi1, Alessandra Spallino1

  • 1Pediatric Unit, Department of Medical and Surgical Sciences of Mothers, Children and Adults, University of Modena and Reggio Emilia, Modena 41121, Italy.

PubMed

Insights

Early-onset absence epilepsy (EOAE) in children under four often has a good prognosis with medication. Atypical absence seizures in this age group present more complex challenges, including genetic factors and poorer neurocognitive outcomes.

Area of Science:

  • Neurology
  • Genetics
  • Pediatrics

Background:

  • Childhood Absence Epilepsy (CAE) typically starts between ages 4-10.
  • Early-onset Absence Epilepsy (EOAE) begins before age 4, often with good treatment outcomes.
  • Atypical absence seizures are longer, may include motor symptoms, and are linked to severe conditions.

Purpose of the Study:

  • Delineate features of EOAE and early-onset atypical absence seizures.
  • Facilitate prompt diagnosis, especially of genetic causes.
  • Optimize patient outcomes through precision therapies.

Main Methods:

  • Retrospective study of 23 pediatric patients with absence epilepsy onset before age 4.
  • Evaluation at the Neuropediatrics Outpatient Clinic of Policlinico of Modena.
  • Focus on clinical and electroencephalographic phenotypes, genetic abnormalities, and treatment response.

Main Results:

  • Children with atypical absences showed complex phenotypes, frequent genetic abnormalities, and less favorable neurocognitive prognosis.
  • Half of the atypical absence subgroup were pharmacoresistant.
  • All EOAE cases achieved seizure freedom, indicating a benign course.

Conclusions:

  • EOAE generally has a favorable prognosis, consistent with existing literature.
  • Early-onset atypical absence seizures present significant challenges, including genetic links and pharmacoresistance.
  • Identifying genetic aberrations is crucial for tailored interventions and improved outcomes in pediatric absence epilepsy.

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
300
Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
177
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
248
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
144
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
415
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
328